Abstract
Introduction
Diabetic foot disorder, the major source of disability and morbidity, is a significant burden for the community and a true public health problem [1] . Diabetic foot ulcerations result from different pathophysiological mechanisms; a clear understanding of them is crucial to reduce their incidence, provide early care, and finally delay the amputation risk. The three main diabetes complications involved in foot ulcerations are neuropathy, peripheral artery disease, and infection [2] . Diabetic neuropathy is the most common complication of diabetes, affecting 50% of diabetic patients [3] . The most important factor related to the development of foot ulcer is peripheral neuropathy, associated with loss of pain sensation. Neuropathy can be associated with peripheral vascular disease and foot deformities [4] .
Peripheral vascular disease is one of the components of the diabetic foot. Diabetic patients should be assessed for lower limb arterial disease. Medical management includes minimization of vascular risk factors, anti-thrombotic therapy, and walking rehabilitation. Vascular testing is required in the presence of a foot wound [5] .
Foot infections are common in patients with diabetes and are associated with high morbidity [6] .
Infection is always the consequence of a preexisting foot wound whose chronicity is facilitated by the diabetic peripheral neuropathy, whereas peripheral vascular disease is a factor of poor outcome, especially regarding the risk for leg amputation [7] .
Peroxisome proliferator-activated receptor gamma (PPARgamma) is an important transcription factor for lipid and glucose metabolism [8] . The peroxisome proliferator-activated receptors (PPARs) are nuclear fatty acid receptors, which contain a type II zinc finger DNA binding motif and a hydrophobic ligand binding pocket. These receptors are thought to play an important role in metabolic diseases such as obesity, insulin resistance, and coronary artery disease. Three subtypes of PPAR receptors have been described: PPARalpha, PPARdelta/beta, and PPARgamma. PPARgamma has high expression in fat, low expression in the liver, and very low expression in the muscle [9] . However, they are also expressed in renal glomerular tissue and in vascular walls, thus participating through various and complex mechanisms, to glomerular and vascular sclerosis and to nephropathy development and progression [10, 11] . We aims investigate Turkish type 2 diabetic patients with/without diabetic foot ulcers and healthy group and examined the contribution of the Pro12Ala (rs1801282) and C478T of the PPARgamma gene polymorphism to the development of diabetic foot.
Material and Method
After Blood samples were taken in the morning after overnight fasting. Serum total-cholesterol, HDLcholesterol, LDL-cholesterol, triglycerides, uric acid, creatinine, thyroid stimulating hormone, glycolizated hemoglobin (4,5-6%), high sensitive C-reactive protein (hs-CRP), erithrocyte sedimentation rate (ESR) and microalbuminuria levels were measured. Biochemical parameters were studied with Roche/Hitachi Moduler autoanalyzer, complete blood count was studied with Roche Symex autoanalyzer.
Foot ulcer is defined as full-thickness skin defect that did not heal within 14 days(16). Wagner classification was used for diabetic foot ulcers. Infection was defined as at least two of the following; purulent discharge, local heat increment, local erythema, lymphangitis, edema, fever and bad odour [13, 14] .
Retinopathy is diagnosed by ophthalmologic evaluation [15] .
Microalbuminuria was diagnosed when albumin excretion rate (AER), measured by radioimmunoassay (RIA), was 30-300 mg/24-hours in at least two out of three 24-hours urine Macrovascular disease is defined as; presence of ischemic heart disease, stroke, transient ischemic attack or peripheral artery disease [13, 15] . Peripheral artery disease is diagnosed by absence of both feet pulses and/or ankle-brachial pressure index [ABPI] lower than 0,90 [16] [17] [18] [19] [20] [21] .
ABPI measurement is made by a hand doppler (Hadeco ES-101EX, 8 Mhz).
Peripheral sensory neuropathy was defined as insensitivity to the 5.07 (10-g) Semmes-Weinstein monofilament at any one of ten sites on either foot (dorsal midfoot, plantar aspect of foot including pulp of the first, third, and fifth digits, the first, third and fifth metatarsal heads, the medial and lateral midfoot and the calcaneus). 
Genotype Analysis

Results
Clinical investigation
Retinopathy, neuropathy and infection were statistically different between diabetic patient groups. Systolic and diastolic blood pressures were significantly different between patients and controls groups (Table 1) . HDL-Cholesterol and TG levels were statistically different between controls and diabetic patients ( Table 2) . 
Frequencies of C/G exon 2 and C/T exon 6 of the PPARgamma gene polymorphism
Genotyping of the Pro12Ala C/G substitution in exon 2 and C478T C/T substitution in exon 6 of the PPARG gene polymorphism for all individuals was performed by PCR-RFLP method. But for quick results, PCR was done by LightCycler System with FastStart Syber Green Master kit (Roche Applied Science, Germany). The distributions of genotype and allele frequencies were compared between diabetic patients and controls ( We analyzed the frequency of C/G exon 2 and C/T exon 6 of the PPARgamma gene in type 2 diabetes mellitus and control groups. The genotype exon 2 distribution did not differ between the control group (CC 90%, CG 8%, GG 2%) and the type 2 diabetes mellitus patients ( CC 98%, CG 2%, GG 0%) (P>0.05) ( Table 3 ). The frequency of the polymorphic G allele was no similar for the group with type 2 diabetes mellitus as for the control group with 1% and 6%, respectively (p<0.05; Table 3 ). The genotype exon 6 distribution did not differ between the control group (CC 82%, CT 18%, TT 0%) and the type 2 diabetes mellitus patients (CC 73%, CT 19%, TT 8%) (P>0.05) ( Table 4 ).
The frequency of the polymorphic T allele was also similar for the group with type 2 diabetes mellitus as for the control group with 17.5% and 9%, respectively (p> 0,05, Table 4 ). Genotype exon 2 frequencies in diabetic patients with diabetic foot were (G/G) 0%, (C/G) 2%;
(C/C) 98% versus (G/G) 0%; (G/C) 2%; (C/C) 98% in those without diabetic foot (p>0.05). The frequency of the polymorphic G allele was 1% in diabetic patients with diabetic foot versus 1%
in those without diabetic foot (P>0.05) ( Table 5 ). Genotype exon 6 frequencies in diabetic patients with diabetic foot were (T/T) 4%, (T/C) 18%;
(C/C) 78% versus (G/G) 12%; (G/C) 20%; (C/C) 68% in those without diabetic foot (p>0.05).
The frequency of the polymorphic T allele was 13% in diabetic patients with diabetic foot versus 22% in those without diabetic foot (P>0.05) ( Table 6 ). 
Discussion
Social deprivation is an important factor, especially for the development of foot ulcers [17] .
However, the most important factor related to the development of foot ulcer is peripheral neuropathy. Diabetic peripheral neuropathy (DPN) is one of the complications of type 2 diabetes mellitus (T2 DM) that decreases the quality of life of T2DM patients. Very few studies have found an association between the development and progression of DPN in T2DM [18] . have studied the relationships between I/D polymorphism of ACE gene and presence of microangiopathic complications in type 2 diabetic patients. There were no significant differences in the frequencies of ACE genotype [20] . Agonism of the peroxisome proliferator-activated receptors (PPARs) has long been an attractive target for antidiabetic therapy due to the role of PPARs in glycemic control and lipid metabolism [21] .
There is not study that development of diabetic foot has PPARgamma gene polymorphism. In our study we investigated a possible association of the G/C exon 2 and T/C exon 6 of the PPARgamma gene polymorphism with the development of diabetic foot in Turkish type 2 diabetes patients. PPARgamma exon 2 and exon 6 gene polymorphism was not associated with risk of the development of diabetic foot in our group of type 2 diabetic patients. Our study suggests that polymorphic G allele may play a specific role(s) in determining diabetic susceptibility, but do not seem to be important in the clinical manifestations of development of diabetic foot.
Our study is the first one in a Turkish population which shows that the the C/G exon 2 and C/T exon 6 of the PPARgamma gene polymorphism was not associated with risk of the development of diabetic foot. Thus, we suggest that the C/G exon 2 and C/T exon 6 of the PPARgamma gene polymorphism is not an independent risk factor for diabetic foot in Turkish type 2 diabetes mellitus patients. Genetic factors in the pathogenesis of diabetic foot may also show any changes in different populations. 
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